NEUROGEN (NRGN) –
-
NRGene Establishes Supree, a Food-Tech Company developing Self-Drying Fruits and Vegetables
-
Above Food Corp. to Acquire AI-based Genomic Assets, Intellectual Property and Trait Development Technology Licensing Rights from NRGene (NRGN)
-
Above Food Corp. to Acquire AI-based Genomic Assets, Intellectual Property and Trait Development Technology Licensing Rights from NRGene
-
Bühler and NRGene collaborate to increase competitiveness of black soldier fly industry
-
Canola Clubroot Disease: Winning the Fight Has Never Been Closer!
-
A High-Resistance ToBRFV Tomato Variety is Within Reach - NRGene and Philoseed Announce Successful Resistance Validation by Customers.
-
Strategic Collaboration to Address the Global Food Crisis: NRGene and Granot Group Develop Elite Varieties for Vertical Farming
-
NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato Varieties
-
NRGene Signs a Strategic Collaboration Agreement with Top Seeds International, a Subsidiary of the Japanese Corporation Mitsui & Co., Ltd.
-
NRGene Accelerates Growth with a New Office and Genotyping Lab in Canada
-
NRGene Launches New Off-the-shelf Soy Genotyping Solution
-
NRGene to Advance Wyffels Hybrids Breeding Program Through Start-to-End Genotyping Solutions
-
Two C-Level Executives Join NRGene to Fortify Its Leadership Team
-
Canola/Rapeseed Pan-Genome Consortium Results Reveal Broad Genetic Diversity of the Crop
-
An Exclusive Agreement for Commercialization of the Autoflower Trait of Cannabis
-
Mapping Key DNA Markers for the Autoflower Trait to Accelerate Breeding Elite Hemp and Cannabis Varieties
-
AI Genomics Company, NRGene, Completes Initial Public Offering on Tel-Aviv Stock Exchange and Raises NIS 100 Million (~US$30 Million)
-
Ligand Pharma (LGND) and Neurogen Corp. (NRGN) Amend Merger Agreement; Ligand to Pay Additional $600K
-
Ligand Pharmaceuticals (LGND) to Acquire Neurogen (NRGN)
-
Neurogen Corp (NRGN) Misses Q4 View By 2c
-
Pacific Growth Downgrades Neurogen (NRGN) to Neutral
-
Unusual 11 Mid-Day Movers 7/14: XING, CRME, STEI, CSGS Higher; NRGN, WM, NCC, FHN Lower
-
Unusual 11 Mid-Day Movers 4/9: EPMD, ONCY, SPR, XRM Higher; MNKD, NRGN, NKTR, PTRY Lower
-
Neurogen (NRGN) Announces $30.6M Private Placement Offering; Cuts Workforce by 45 Positions
-
Unusual 11 Mid-Day Movers 3/20: CCOW, NRGN, DITC, MFA Higher; EPIX, CIT, BGP, TMA Lower
-
Credit Suisse Starts Neurogen (NRGN) at Neutral
-
ThinkEquity Starts Neurogen (NRGN) at Buy
-
Neurogen (NGRN) Announces Executive Management Changes
-
Neurogen (NRGN) Continues Studies in Collaboration with Merck (MRK) for Investigational Pain Drug
-
Neurogen (NRGN) Files $100 Million Mixed Securities Shelf
-
Neurogen Corporation (NRGN) Reports a Q1 Loss
-
Neurogen (NRGN) Reports a Q4 Loss, Revs Light
-
CIBC Starts Neurogen (NRGN) at Sector Outperformer
-
Neurogen (NRGN) Raises $40 Million In Registered Direct Offering of Common Stock
-
Neurogen (NRGN) Sells 7M Shares at $5.72
-
Neurogen (NRGN) Acquires Development and Commercialization Rights to Aplindore
-
EARNINGS DUE OUT AFTER THE CLOSE TODAY AND BEFORE THE OPEN TOMORROW
-
Pacific Growth Upgrades Neurogen (NRGN) to Buy
-
Neurogen (NRGN) Reports Phase II Drug Candidate for Insomnia, NG2-73, Meets Primary Endpoints
-
Earnings Due Out After The Bell Today And Before The Open Tomorrow
-
NRGN Announces Results of Phase I Multiple Ascending Dose Trial for Insomnia Drug
-
Merriman Curhan Starts NRGN at Buy
-
NRGN Announces Results of First-In-Human Trial For Insomnia Drug
Back to NRGN Stock Lookup
